GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
94
c/trialwatch·posted 4 months ago by u/first_hundred

hazard ratio is the most under-discussed thing on this board

Readout

hazard ratio is the most under-discussed thing on this board. Not a hot take, just something I have not seen said plainly here.

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.

139 up / 45 down75% upvoted11 commentsid 5jf4dw27 Mar 2026

11 comments

11 in this archive, depth 5

best — the order this archive was captured in

u/hsa_math13 points·4 months ago

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

replysharereportpermalink
u/trialwatch_theoMOD7 points·4 months ago

Retitled: the original quoted a diabetes endpoint as an obesity result.

replysharereportpermalink
u/first_hundredOP4 points·4 months ago

Which trial, and which arm?

replysharereportpermalink
u/rohan_cardoso4 points·4 months ago

The press release said that; the publication says something more hedged. Worth reading both.

replysharereportpermalink
u/injection_site_iris5 points·4 months ago

What was the comparator?

replysharereportpermalink
u/rohan_cardoso9 points·4 months ago

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

replysharereportpermalink
u/nayeli_fonseca3 points·4 months ago

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

replysharereportpermalink
u/sten_palacios2 points·4 months ago

Read a press release and the publication three months apart. The hedging in the second one was substantial.

replysharereportpermalink
u/rina_sobczak1 point·4 months ago

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

replysharereportpermalink
u/camila_vasquez1 point·4 months ago

Went looking for the registered protocol to see whether the endpoint had changed.

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

replysharereportpermalink
u/first_hundredOP2 points·4 months ago

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.